ProCE Banner Activity

Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC

Slideset Download
Conference Coverage
Dual immune checkpoint inhibition with tiragolumab plus atezolizumab achieved meaningful improvement in ORR and PFS with comparable safety vs placebo plus atezolizumab, with the greatest benefit among patients with PD-L1 TPS ≥ 50%.

Released: June 05, 2020

Expiration: June 04, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono